Company intelligence / Profile preview

FAScinate Therapeutics

San Diego, California, United Statesfascinatetherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

KM-819, the company's lead drug candidate, has completed Phase 1 clinical trials demonstrating an acceptable safety profile and has been cleared by the FDA for Phase 2 trials as of November 2021. The drug is designed to slow or stop the progression of Parkinson's disease by inhibiting FAF1 proteins that promote cell death, protecting dopaminergic neurons.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

KM-819

Phase 2

Indications: Parkinson's disease, Multiple system atrophy

Beyond the preview

Go deeper on FAScinate Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAScinate Therapeutics.